Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

09:47
Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL?1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in...

07:35
Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with...

07:30
At a late-breaking oral presentation (LBA15) at the virtual 2021 ESMO Congress today, Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, reported positive results from its pivotal Phase III TULIP®...


18 september 2021

07:59
Epic Sciences, Inc.'s (Epic) Comprehensive Cancer Profilingtm Platform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO...


17 september 2021

20:00
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced...

20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced...

18:05
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. announced today ahead of the European Society for Medical Oncology (ESMO) Congress 2021 that XTANDI® (enzalutamide) improved overall survival (OS)...

10:01
Tools4Patient presented data at the MDS Congress 2021 that predicted the placebo response in Parkinson's disease (PD) in a multi-center, multi-national clinical study. This approach ? called Placebell©tm ? to mitigate the negative impact of the...

09:15
Vuzix® Corporation , ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Vuzix M400 Smart Glasses were recently featured in a clinical pilot study that examined...

09:00
A leading medical AI provider Lunit today announced that its AI for tissue analysis has been applied in a clinical trial for drug development, accurately predicting the patients' response to immunotherapy. Including this major finding, the company...

08:38
Debbie's Dream Foundation: Curing Stomach Cancer (DDF) has partnered with the American Association for Cancer Research (AACR) to encourage and inspire more research in the field of gastric cancer through a $200,000 research grant. The AACR-Debbie's...

08:00
InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng...

07:57
NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim...

07:35
Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from...

07:30
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1)...

07:16
A leading medical AI provider Lunit today announced that its AI for tissue analysis has been applied in a clinical trial for drug development, accurately predicting the patients' response to immunotherapy. Including this major finding, the company...

03:06
Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders today announces the dosing of the first patients in the company's global phase 3 trial of C21 in COVID-19...


16 september 2021

20:00
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced...

19:02
Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded Phase 2 clinical trial called...

18:10
Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant...

18:00
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company, announced that an ePoster presenting pre-clinical data...

17:00
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced an update for its lead osteoarthritis (OA) drug candidate EP-104IAR....

12:00
Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic...

11:30
According to the new market research report "eClinical Solutions Market by Clinical trial phases, Product (CDMS, EDC, CTMS, eCOA, RTSM, ETMF, Analytics, Integration, Safety), Delivery (Web-based, On demand, On premise, Cloud), End user (Pharma &...

09:05
Force Therapeutics, the leading patient engagement platform and research network, exceeded 110 clinical research publications today. This milestone was made possible through more than a decade of delivering digital musculoskeletal (MSK) care to...

09:00
Two promising Ontario-based oncology innovations are the latest recipients of early-stage seed capital through FACIT's Prospects Oncology Fund. The breakthrough diagnostic technologies were developed by Dr. Matthew Cecchini and Dr. Subrata...

09:00
Therapeutic Solutions International, Inc., , reported today new data demonstrating positive effects when its commercially available nutraceutical, QuadraMunetm, is administered together with ivermectin in animals suffering from similar biological...

08:45
Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-resistance oncology therapeutic, has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in a validated I/O...

08:37
Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic hyperplasia (BPH), today announced the availability of...

08:30
Interactive response technology (IRT) manages clinical trial randomization and getting the right investigational product (IP) to the right patient at the right time. What happens when trials do not mature as expected? Perhaps enrollment is slow and...

08:01
COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND)...

08:00
AbbVie today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely active ulcerative colitis to the U.S....

08:00
TriviumVettm, an animal health research and development company focused on addressing unmet needs in companion animal medicine, today announced that the Food and Drug Administration's Centre for Veterinary Medicine has determined that the company can...

07:05
Phio Pharmaceuticals Corp. , a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLtm) therapeutic platform, today announced results of a new study showing that...

07:00
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, presented preclinical data demonstrating that the...

06:05
Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway with COVID-19 treatment development in more broaden...

06:00
- The mechanism of action of the investigational medicine sibofimloc positions it as a potential novel and important treatment option for Crohn's disease - Oral sibofimloc is a first-in-class gut-restricted small molecule FimH-blocker designed to...

05:06
Laekna Therapeutics, an emerging innovative biotech company based in China's "Zhangjiang Pharma Valley" and New Jersey, USA, focusing on the development of ground-breaking innovative therapies to treat cancer and liver diseases, reported positive...

05:00
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today announced initial results from the Phase 1 trial of NOUS-209, the first clinical results for the company. NOUS-209, an...

04:30
Amgen today announced the first combination study results from the Phase 1b/2 CodeBreaK 101 study, the most comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer (CRC). These new data show...

03:03
Medivir AB  invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Society for Medical Oncology (ESMO) congress. The conference call...

03:00
Ellipses Pharma, the UK-based global drug development company, has today announced a significant increase in its portfolio of potential treatments for a range of cancers....

03:00
Intravacc, a global leader in translational research and the...

02:31
Leap Therapeutics, Inc. , a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical...


15 september 2021

14:05
Albert Einstein College of Medicine has received a five-year, $5 million grant from the National Institutes of Health (NIH) to support the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (RFK IDDRC), which has been at the...

11:47
The results of the prospective randomized DECART-2 study were released on July 15, 2021 in the journal, Diagnostics. Physicians...

11:41
NYU Langone Health, as the Clinical Science Core (CSC) for the National Institutes of Health's RECOVER Initiative, has, since the announcement of the beginning of its operations on June 10, convened more than 100 researchers from 35 institutions as...

10:47
Brook Remote Patient Monitoring (RPM) has been selected to enhance data collection for the BLOSSOM clinical trial now under way for the Kidney Research Institute, a collaboration between Northwest Kidney Centers and the University of Washington....

09:30
Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, today announced the completion of the company's $55.0...

09:15
Ampio Pharmaceuticals , a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III...

1 2 3 4 5 6 7 8 9 10